Literature DB >> 29883861

Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study.

Josep Maria Haro1, Carlo Altamura2, Ricardo Corral3, Helio Elkis4, Jonathan Evans5, Marie-Odile Krebs6, Mathias Zink7, Ashok Malla8, José Ignacio Méndez9, Corrado Bernasconi10, Justine Lalonde10, Anna-Lena Nordstroem10.   

Abstract

The Pattern study was conducted to provide longitudinal observational data for individual patients with persistent symptoms of schizophrenia. Pattern is an international, multicenter, non-interventional, prospective cohort study of schizophrenia outpatients who were not considered to be in recovery. In the longitudinal phase reported herein, patients were assessed over 1 year using different clinical rating scales. Patient management followed routine local clinical practice. Primary outcome was disease state, defined by the Positive and Negative Syndrome Scale (PANSS), Negative Symptom Factor Score (NSFS), Positive Symptom Factor Score (PSFS), and Personal and Social Performance (PSP) Scale. In total, 1344 protocol-compliant patients (70.9% male) were included. Patients showed a high stability in disease state between consecutive study visits. Persistent negative persistent symptoms and symptomatic remission were the most prevalent and stable disease states. Patients in relapse generally transitioned to negative persistent symptoms or to symptomatic remission. PANSS, PSP, and quality of life ratings remained relatively stable. Relapses occurred in 10% of patients; probability of relapse was associated with younger age, extra-pyramidal symptoms, and more antipsychotic medications. Despite treatment, schizophrenia symptoms tend to remain stable over time, without overall improvement. One of the greatest challenges in schizophrenia is attainment of full symptom remission.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Naturalistic; Negative symptoms; Positive symptoms; Recovery; Relapse; Remission

Mesh:

Substances:

Year:  2018        PMID: 29883861     DOI: 10.1016/j.psychres.2018.04.005

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

1.  Influence of More Than 5 Years of Continuous Exposure to Antipsychotics on Cerebral Functional Connectivity of Chronic Schizophrenia.

Authors:  Qi Miao; Chengcheng Pu; Zhijiang Wang; Chao-Gan Yan; Chuan Shi; Qingjiu Cao; Xijin Wang; Zhang Cheng; Xue Han; Lei Yang; Yunyao Lai; Yanbo Yuan; Hong Ma; Keqing Li; Nan Hong; Xin Yu
Journal:  Can J Psychiatry       Date:  2020-02-06       Impact factor: 4.356

2.  Cognitive Functioning and Schizotypy: A Four-Years Study.

Authors:  Penny Karamaouna; Chrysoula Zouraraki; Stella G Giakoumaki
Journal:  Front Psychiatry       Date:  2021-01-08       Impact factor: 4.157

Review 3.  The Association of the Gut Microbiota with Clinical Features in Schizophrenia.

Authors:  Annamarie Nocera; Henry A Nasrallah
Journal:  Behav Sci (Basel)       Date:  2022-03-25

Review 4.  Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.

Authors:  Kah Kheng Goh; Cynthia Yi-An Chen; Tzu-Hua Wu; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

5.  Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting.

Authors:  Young-Chul Chung; Yen Kuang Yang; Ahmad Hatim Sulaiman; Paul Bergmans; Wilson Tan
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-08-31       Impact factor: 3.731

6.  Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design.

Authors:  Lyliana G Nasib; Iris E Sommer; Inge Winter-van Rossum; Jacqueline de Vries; Shiral S Gangadin; Priscilla P Oomen; Gurmeet Judge; Renske E Blom; Jurjen J Luykx; Nico J M van Beveren; Natalie D Veen; Rune A Kroken; Erik L Johnsen
Journal:  Trials       Date:  2020-06-08       Impact factor: 2.279

7.  Simple Mobile technology health management tool for people with severe mental illness: a randomised controlled feasibility trial.

Authors:  Frank Röhricht; Raguraman Padmanabhan; Paul Binfield; Deepa Mavji; Sally Barlow
Journal:  BMC Psychiatry       Date:  2021-07-16       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.